Fig. 2.

SABA prescriptions by investigator-classified asthma severity in the 12 months before the study visit in the SABINA III Turkey Cohort. *Asthma severity data are reported for 568 patients and not for the six patients with missing data or the five patients erroneously categorised under primary care. ^†The category of patients classified as having 0 SABA canister prescriptions included patients using non-SABA relievers, non-inhaler forms of SABA and/or SABA purchased OTC. Missing data for the overall population: n = 136; mild asthma: n = 11; moderate-to-severe asthma: n = 125. OTC, over the counter; SABA, short-acting β₂-agonist; SABINA, SABA use IN Asthma